A box of Wegovy pills arranged at a pharmacy in Provo, Utah, US, on Thursday, Jan. 15, 2026.The Food and Drug Administration said Novo Nordisk's TV advertisement for its newly launched Wegovy pill for obesity included "false or misleading" claims about the medicine's abilities and benefits to patients.In a letter to Novo dated Feb. 5, the FDA said the ad misbrands the oral drug, making its distribution a violation of federal law. The agency requested that the drugmaker take immediate action to address the v ...

Core Insights - Hims & Hers Health's stock plummeted 25% following the announcement of its plan to sell a compounded version of Wegovy for $49 per month, significantly undercutting Novo Nordisk's pricing [1][4] - Novo Nordisk responded with a lawsuit against Hims & Hers, seeking a permanent ban on the sale of its Ozempic lookalike pill and any compounded versions of its drugs [5][6] - The FDA indicated it would take action against Hims & Hers, potentially restricting access to necessary ingredients for manufacturing similar products [2][4] Company Actions - Hims & Hers initially planned to sell a pill version of Ozempic but reversed its decision by Saturday, indicating a retreat in the face of legal and regulatory pressure [3][4] - The company gambled on the FDA's leniency regarding the copying of Novo Nordisk's GLP-1 weight loss drug but ultimately faced significant legal challenges [4][5] Legal Implications - Novo's lawsuit targets Hims & Hers' ability to compound GLP-1 weight loss drugs using semaglutide, which could result in the loss of Hims & Hers' GLP-1 business if Novo wins [6] - The lawsuit emphasizes Novo's enforcement of its patent rights, which could have broader implications for the telehealth company's product offerings [6]

Morning Trade Live. Let's focus on the latest development in the weight loss drug trade. Novo Nordisk is high this morning and hims and hers is moving in the other direction quite substantially.After Hims pulled its generic wegovy pill. Both stocks have had a rough start to 2026, but today's move is a bright spot for Novo investors, so that is the focus of the morning trade. Joining us now for a closer look is Marley Kayden.Very good morning. Happy Monday Marley. So a nice shot in the arm now for Novo.It ne ...

Core Insights - Novo Nordisk faces significant challenges in 2023, primarily due to competition from Eli Lilly and setbacks in its clinical studies [2][3] - The company is attempting to expand its GLP-1 drug offerings into new markets, such as obesity treatment, but has encountered difficulties [3] - Eli Lilly's stock is performing exceptionally well, with a valuation reaching one trillion dollars, indicating strong market confidence in its products [4][6] Company Performance - Novo Nordisk has experienced a tough year, marked by pipeline issues and a failed clinical study [3] - The company plans to launch a new pill next year utilizing peptide technology, which may help regain market traction [5] - Eli Lilly is currently in a stronger position with leading products like Mounjaro and Zepbound, which are expected to drive future growth [6] Market Comparison - There is a competitive landscape between Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, with both drugs serving similar purposes but having different consumer perceptions [7][8] - Physicians report that patients tend to perform better on Mounjaro compared to Wegovy, suggesting a potential preference in the market [8] - Eli Lilly's upcoming drug, orphaglyphron, is anticipated to have significant market potential, with peak sales estimates between 30 to 50 billion [6]

Core Insights - General Mills, Inc. (NYSE:GIS) is facing significant challenges due to high food and input costs, which are impacting profit margins and pricing strategies [2] - The company is considered part of the inflation complex, with concerns that it may need to lower food prices to maintain sales volume, potentially leading to further stock price declines [2] - There is speculation about the potential for a takeover, as the food sector is being adversely affected by GLP-1 weight loss drugs [1] Company Overview - General Mills produces a variety of branded foods, including cereals, snacks, frozen meals, baking products, yogurt, and pet foods, with well-known brands such as Cheerios, Betty Crocker, and Haagen-Dazs [2] - The company is currently under scrutiny for its performance in the stock market, with analysts noting that its situation has not improved significantly [2] Market Context - The food industry, particularly companies like General Mills, is experiencing pressure from rising costs and inflation, which could lead to a decrease in profitability [2] - There is a suggestion that investors may find better opportunities in AI stocks, which are perceived to have higher upside potential and lower downside risk compared to traditional food stocks like General Mills [2]

Core Viewpoint - DexCom's stock has declined by 25% since the beginning of 2025, despite a generally positive stock market environment, raising questions about its future performance and potential buying opportunities [1][2]. Financial Performance - DexCom reported third-quarter earnings on October 30, with revenue of $1.2 billion, reflecting a year-over-year increase of 22%. However, this growth is compared to a period of slow growth last year, leading to skepticism among investors regarding its sustainability [4]. Market Concerns - Investors are increasingly bearish on DexCom due to the emergence of GLP-1 weight loss drugs, which may reduce the demand for continuous glucose monitoring (CGM) devices. These drugs have shown effectiveness in lowering glucose levels for diabetes patients, potentially impacting DexCom's market [5][6]. Stock Valuation - DexCom's stock is currently trading at levels not seen since the COVID-19 crash of 2020, with a forward price-to-earnings (P/E) multiple of 26, which is lower than its historical average. This situation may present a buying opportunity for investors [7][8].

Group 1 - The Hershey Company has faced significant struggles over the past two and a half years, largely attributed to the impact of GLP-1 weight loss drugs on the packaged food industry [1] - Despite the challenges, there is a belief that the worst may be behind Hershey, suggesting potential for recovery [1] - The company is recognized for its iconic brands, including Hershey's, Reese's, Kit Kat, and SkinnyPop, and offers a variety of products such as chocolates, gums, mints, and baking ingredients [2] Group 2 - While Hershey is acknowledged as a potential investment, there are opinions that certain AI stocks may present greater upside potential and lower downside risk [3]

Company Overview - Hershey's stock has experienced a significant decline, dropping from a high of 196 to around 169 in recent weeks, indicating a troubling trend for shareholders [2][3] - The company has been struggling for the past two and a half years, primarily due to the impact of weight loss drugs on consumer behavior and high cocoa prices [3][4] Recent Developments - A new CEO, Kirk Tanner, was appointed in mid-August, bringing experience from Wendy's and PepsiCo, which was seen as a positive change for the company [5] - Despite the leadership change, Hershey's recent earnings report was complex, leading to a cut in the full-year earnings forecast due to tariffs and cocoa price volatility management costs [6] Market Reaction - Following the earnings report, the stock initially spiked but quickly fell back, reflecting ongoing volatility and investor uncertainty [6][7] - The stock's performance has been described as choppy and has worsened in recent weeks, contributing to a negative sentiment around the company [7]

Core Viewpoint - Despite recent declines, certain growth stocks are still considered strong long-term investment opportunities due to their potential for recovery and growth [1]. Group 1: Viking Therapeutics (VKTX) - Viking Therapeutics' stock is down nearly 57% from its 52-week high of $81.73, primarily due to concerns over the high discontinuation rate of its leading drug VK2735 in clinical trials [4][5]. - The company is still developing VK2735, with an injectable version in late-stage trials, which could serve as a significant growth catalyst if approved [5][7]. - Currently, Viking Therapeutics has a market cap of $4 billion, with a current stock price of $38.17, and it has shown potential for weight loss of up to 14.7% after 13 weeks of treatment [6][7]. Group 2: Cava Group (CAVA) - Cava Group's share prices have decreased over 46% this year and are down nearly 65% from their 52-week high of $172.43, attributed to a slowdown in growth [8][9]. - The company's same-store sales growth was only 2.1% in the most recent quarter, a significant drop from 14.4% a year ago, yet it remains positive amid challenging economic conditions [9]. - Cava Group has plans to expand from 400 to 1,000 locations by 2032, indicating potential for future growth despite current challenges [9][11]. Group 3: Figma (FIG) - Figma's stock has fallen from a high of $142.92 to around $53, reflecting a significant decline since its public debut [12][15]. - The company has a market cap of $24 billion and reported $249.6 million in revenue for the period ending June 30, representing a 41% increase year-over-year [13][15]. - Figma's valuation is comparable to Adobe's previous bid of $20 billion for the company, suggesting it may be undervalued at its current price [13][15].

Core Insights - Novo Nordisk and Eli Lilly have been among the top-performing healthcare stocks, with Novo Nordisk increasing by 400% and Eli Lilly by 67% over the past five years, despite a recent sell-off in Novo Nordisk's value [1][2] Group 1: Market Position and Growth Potential - Both companies are considered underrated despite their significant past performance, indicating potential for further investment [2] - The market for GLP-1 weight loss drugs is rapidly expanding, with many pharmaceutical companies developing treatments, presenting a substantial growth opportunity [4] - Eli Lilly and Novo Nordisk hold a competitive advantage as they already have approved GLP-1 treatments on the market: Zepbound and Wegovy [5] Group 2: Pricing and Accessibility - The high cost of GLP-1 drugs, with Zepbound priced over $1,000 and Wegovy over $1,300 for a 28-day supply, poses a barrier for consumers without insurance [5][9] - The Trump administration is reportedly considering covering GLP-1 weight loss drugs under Medicare and Medicaid, which could significantly boost market growth for these companies [6][9] Group 3: Broader Health Benefits - GLP-1 drugs are linked to various health benefits beyond weight loss, including treatment for obstructive sleep apnea and reducing the risk of serious heart problems in obese adults [7] - Ongoing research may uncover additional applications for GLP-1 drugs, potentially leading to stronger growth rates for both companies [10]